Amedisys Inc (NASDAQ:AMED)’s share price was down 10% during mid-day trading on Friday . The company traded as low as $97.38 and last traded at $98.20. Approximately 1,084,862 shares traded hands during mid-day trading, an increase of 237% from the average daily volume of 321,858 shares. The stock had previously closed at $109.08.
A number of equities analysts have recently issued reports on AMED shares. Royal Bank of Canada raised their price target on Amedisys to $115.00 and gave the stock an “outperform” rating in a research note on Friday, August 3rd. SunTrust Banks raised their price target on Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Cantor Fitzgerald started coverage on Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price target on the stock. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 16th. Finally, Robert W. Baird raised their price target on Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Thursday, October 11th. Six equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Amedisys has an average rating of “Buy” and an average target price of $97.08.
The firm has a market capitalization of $3.13 billion, a P/E ratio of 44.43, a price-to-earnings-growth ratio of 1.50 and a beta of 1.00. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.30.
In related news, insider David B. Pearce sold 398 shares of the firm’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total value of $48,440.58. Following the transaction, the insider now directly owns 11,818 shares of the company’s stock, valued at approximately $1,438,368.78. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Amedisys by 7.5% during the second quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock valued at $459,945,000 after acquiring an additional 377,153 shares during the period. Acadian Asset Management LLC raised its holdings in Amedisys by 148.0% during the second quarter. Acadian Asset Management LLC now owns 191,162 shares of the health services provider’s stock valued at $16,338,000 after acquiring an additional 114,077 shares during the period. Sei Investments Co. raised its holdings in Amedisys by 762.0% during the second quarter. Sei Investments Co. now owns 123,582 shares of the health services provider’s stock valued at $10,562,000 after acquiring an additional 109,246 shares during the period. Pier Capital LLC bought a new stake in Amedisys during the second quarter valued at about $8,770,000. Finally, DE Burlo Group Inc. bought a new stake in Amedisys during the second quarter valued at about $6,892,000. 93.17% of the stock is currently owned by institutional investors.
Amedisys Company Profile (NASDAQ:AMED)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
See Also: Stock Symbol
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.